Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
Condition: Inclusion Body Myositis Intervention: Drug: Arimoclomol Sponsor: Orphazyme Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Inclusion-Body Myositis | Research